Falk Pharma and Renexxion gain FDA and EMA backing for naronapride

The two companies have cleared End of Phase 2 meetings with both regulators and plan to initiate a global Phase 3 gastroparesis programme in H1

Falk Pharma and Renexxion gain FDA and EMA backing for naronapride

Dr. Falk Pharma and Renexxion have secured regulatory alignment from both the US Food and Drug Administration and the European Medicines Agency on a Phase 3 development programme for naronapride in gastroparesis, following successful End of Phase 2 meetings with each agency.

The agreement covers the overall trial architecture, including separate studies for diabetic and idiopathic gastroparesis sub-populations, participant numbers, and the use of the ANMS-GCSI-DD instrument as the primary and key secondary endpoint measure. The companies said the FDA also agreed that NDA-enabling studies in specific patient populations can run in parallel with the Phase 3 programme, a concession that the partners believe could compress the overall development timeline. A global programme start is targeted for the first half of 2027.

The drug and the data behind it

Naronapride is an oral prokinetic designed to act locally within the gastrointestinal tract. Its dual mechanism targets both the 5-HT4 receptor and the dopamine D2 receptor on the luminal surface of the intestinal wall, aiming to restore coordinated gut motility while limiting systemic exposure. The compound has now completed nine Phase 1 and five Phase 2 trials across multiple GI indications, including gastro-oesophageal reflux disease, erosive oesophagitis, and chronic idiopathic constipation.

The regulatory meetings followed positive topline results from MOVE-IT (NCT05621811), a randomised, placebo-controlled Phase 2b trial in adults with both diabetic and idiopathic gastroparesis. Full data from MOVE-IT have not been published in a peer-reviewed journal, and the companies have not disclosed the primary endpoint result or adverse event rates in this announcement.

Peter Milner, chairman and chief executive of Renexxion, said: "Naronapride was designed to act locally in the gut while limiting systemic exposure. With our Phase 3 plan defined, we can test again whether that design can help patients with gastroparesis and tackle an important unmet medical need."

Market context and competitive landscape

Gastroparesis affects an estimated 22 per 100,000 people across the US and Europe, yet approved long-term pharmacological options remain sparse. Metoclopramide carries a black-box warning for tardive dyskinesia with prolonged use, and domperidone is restricted or unavailable in several major markets owing to cardiac safety concerns. That regulatory and safety gap has attracted a number of development-stage programmes targeting prokinetic mechanisms with improved tolerability profiles.

Naronapride's locally acting design is positioned by the companies as a potential differentiator from older systemic prokinetics. If the Phase 3 programme confirms the Phase 2b signal, it would compete directly with any approved therapies as well as other candidates in late-stage development for the same indication. The FDA's willingness to permit parallel NDA-enabling studies is a meaningful procedural advantage that could bring a filing date forward relative to a sequential approach. Investors will be focused on the Phase 3 protocol details, expected enrolment timelines, and any interim efficacy benchmarks once the trial initiates next year.